血清CA125、CA72-4与人附睾分泌蛋白4检测在卵巢癌早期诊断中的临床价值

Objective To explore the clinical values of combined detection of serum CA125, CA72-4 and HE4 levels in the early diagnosis of ovarian cancer. Methods The serum levels of CA125, CA72-4 and HE4 in 111 patients with ovarian cancer, 130 patients with benign ovarian disease and 90 healthy female controls were measured by electrochemical luminescence immunoassay (ECLIA) and enzyme-linked immunosorbent assay (ELISA) methods. The diagnostic values of the three markers were analyzed separately and combinedly in ovarian cancer. Results The serum levels of CA125, CA72-4 and HE4 of ovarian cancer patients were significantly higher than those of benign ovarian disease patients and healthy controls(Ps ＜ 0. 01). The positive expression rate of HE4(63.5%) in patients with stage Ⅰ ovarian cancer was significantly higher than that of CA125(55. 8%) and CA72-4 (42. 6%)(Ps ＜ 0. 05) . The combined detection of the three markers may improve the overall accuracy of the early diagnosis of ovarian cancer to 75.8%. The diagnostic sensitivity of serum CA125 was relatively higher in serous cystadenocarcinoma, endometrioid carcinoma and poorly differentiated adenocarcinoma; the diagnostic sensitivity of serum CA72-4 was relatively higher in mucinous cystadenocarcinoma and endometrioid carcinoma; the diagnostic sensitivity of serum HE4 was relatively higher in serous cystadenocarcinoma and endometrioid carcinoma. Conclusion CA125 can serve as the first choice of tumor maker in the diagnosis of ovarian cancer, and the combined detection of serum levels of CA125, CA72-4 and HE4 may increase the diagnostic sensitivity of stage Ⅰ ovarian cancer.     

血清CA153、CA125和CEA联合检测在乳腺癌诊断中的应用

Objective To study the clinical singificance of serum tumor markers (CA153, CA125 and CEA) in doagnosis of breast cancer. Methods Electrochemiluminescence immunoassay (ECLIA) was used to analyze serum levels of CA153,CA125 and CEA in 55 patients with breast canc-er (breast cancer group),20 patients with benign breast lesions (benign breast lesion group) and 20 healthy controls (healthy control group). Results The levels of CA153, CA125 and CEA in breast cancer group were significantly higher than those in healthy control group (P<0.05); the levels of CEA and CA153 in breast cancer group were significantly higher than those in benign breast lesion group (P<0.05);the level of CA153 in postoperative patients was statistically lower than that in pre-operative patients (P<0.05);the levels of CEA and CA153 in breast cancer patients with stage Ⅲ and Ⅳ were significantly higher than those in healthy controls (P<0.05); the level of CA153 with stage Ⅲ and Ⅳ was higher than that in ones with stage Ⅰ and Ⅱ. The combined dection of CA153, CA125 and CEA in breast cancer patients increased the experimental sensitivity to 53.8% and specific-ity to 83.3%. Conclusion Detections of CA153,CA125 and CEA contribute to diagnosis of breast cancer. CA153 and CEA are of clinical practical value in differential diagnosis of benign and malignant breast tumor,monitoring of course of breast cancer.     

联合检测CEA、NSE和CYFRA21-1在肺癌诊断中的价值

Objective To investigate the diagnostic value of Joint determination of CEA,NSE and CYFRA21-1 in serum from patients with lung cancer.Methods Detected the CEA、NSE、CYFRA21-1 in different type patients with lung cancer.Results In lung cancer group,the levels of CEA,NSE and CYFRA21-1 were significantly higher than those group of benign lung disease (P<0.05).The sensitivity of joint measurement CEA,NSE and CYFRA21-1 was significantly higher than that of each tumor marker(P<0.05).Conclusion Joint measurement of CEA,NSE and CYFRA21-1 is helpful to diagnosis of lung cancer.     

联合检测CEA、NSE和CYFRA21-1在肺癌诊断中的价值

Objective To investigate the diagnostic value of Joint determination of CEA,NSE and CYFRA21-1 in serum from patients with lung cancer.Methods Detected the CEA、NSE、CYFRA21-1 in different type patients with lung cancer.Results In lung cancer group,the levels of CEA,NSE and CYFRA21-1 were significantly higher than those group of benign lung disease (P<0.05).The sensitivity of joint measurement CEA,NSE and CYFRA21-1 was significantly higher than that of each tumor marker(P<0.05).Conclusion Joint measurement of CEA,NSE and CYFRA21-1 is helpful to diagnosis of lung cancer.     

67例肺癌ECT全身骨显像及血清Cyfra21-1、NSE、CEA、CA125联合测定分析

Objective To explore the correlation between Cyfra21-1、 NSE、 CEA、CA125 and the bone metastasis in lung cancer.Methods Images were obtained on a gamma camera (E.CAM,Siemens,Erlangen,Germany)using 99mTC-MDP as a skeletal imaging agent.67 cases diagnosed as lung cancer were performed by ECT bone imaging,serum concentration of Cyfra21-1,NSE,CEA and CA125 were measured among 30 healthy individual,33 patients with pulmonary tuberculosis and 67 patients with lung cancer by electrogenerated chemiluminescence(ECL) (Roche,Germany).Results The serum Cyfra21-1、NSE、CEA、CA125 from lung cancer were higher than that of controls group and pulmonary tuberculosis group(P<0.01).and the pleural Cyfra21-l and NSE were significantly higher than that in serum.In lung cancer,there are correlation between tumor marker and its pathological types.Cyfra21-1 concentration in squamous cell carcinoma were significantly higher than that of other lung cancers(P<0.01),NSE level in small cell lung cancer were significantly higher than that other lung cancers(P<0.01).33 patients with lung cancer had no obvious sign of bone metastases among 67 cases (accounting for 49.3%),34 patients had bone metastases with varying degrees(accounting for 50.7 % ) ;Adenocarcinoma has highest incidence of bone metastasis( 64 % ),followed by small cell lung cancer and squamous cell carcinoma.Cyfra21-land NSE level is highest in cases with wide spread bone metastasis,followed by those with part bone metastasis and without bone metastasis in turn.Conclusion There are relationship between tumor marker and bone metastasis of lung cancer.Multiple bone metastases often were accompanied by obvious change of serum tumor marker.Cyfra21-lis a useful tool in diagnosis of non-small cell lung cancer,especially in squamous cell carcinoma.NSE is useful to identify the small cell lung cancer.Combined determination of Cyfra21-1,NSE,CEA and CA125 can improve sensitivity,accuracy and positive rate of diagnosis lung cancer.It seems that the whole body bone imaging combined Cyfra21-1,NSE,CEA and CA125 detection have important clinical value in diagnosis and identification of lung cancer.     

67例肺癌ECT全身骨显像及血清Cyfra21-1、NSE、CEA、CA125联合测定分析

Objective To explore the correlation between Cyfra21-1、 NSE、 CEA、CA125 and the bone metastasis in lung cancer.Methods Images were obtained on a gamma camera (E.CAM,Siemens,Erlangen,Germany)using 99mTC-MDP as a skeletal imaging agent.67 cases diagnosed as lung cancer were performed by ECT bone imaging,serum concentration of Cyfra21-1,NSE,CEA and CA125 were measured among 30 healthy individual,33 patients with pulmonary tuberculosis and 67 patients with lung cancer by electrogenerated chemiluminescence(ECL) (Roche,Germany).Results The serum Cyfra21-1、NSE、CEA、CA125 from lung cancer were higher than that of controls group and pulmonary tuberculosis group(P<0.01).and the pleural Cyfra21-l and NSE were significantly higher than that in serum.In lung cancer,there are correlation between tumor marker and its pathological types.Cyfra21-1 concentration in squamous cell carcinoma were significantly higher than that of other lung cancers(P<0.01),NSE level in small cell lung cancer were significantly higher than that other lung cancers(P<0.01).33 patients with lung cancer had no obvious sign of bone metastases among 67 cases (accounting for 49.3%),34 patients had bone metastases with varying degrees(accounting for 50.7 % ) ;Adenocarcinoma has highest incidence of bone metastasis( 64 % ),followed by small cell lung cancer and squamous cell carcinoma.Cyfra21-land NSE level is highest in cases with wide spread bone metastasis,followed by those with part bone metastasis and without bone metastasis in turn.Conclusion There are relationship between tumor marker and bone metastasis of lung cancer.Multiple bone metastases often were accompanied by obvious change of serum tumor marker.Cyfra21-lis a useful tool in diagnosis of non-small cell lung cancer,especially in squamous cell carcinoma.NSE is useful to identify the small cell lung cancer.Combined determination of Cyfra21-1,NSE,CEA and CA125 can improve sensitivity,accuracy and positive rate of diagnosis lung cancer.It seems that the whole body bone imaging combined Cyfra21-1,NSE,CEA and CA125 detection have important clinical value in diagnosis and identification of lung cancer.     

血清四种肿瘤标记物联合检测对肺癌的诊断价值

目的 探讨血清癌胚抗原(CEA)、CA125、CA153、CA199联合检测对肺癌的诊断价值.方法 用化学发光免疫分析法测定58例肺癌患者、38例肺良性病变患者及40名健康体检者血清CEA、CA125、CA153、CA199的含量,评价四项肿瘤标记物联合应用对肺癌的诊断价值.结果 肺癌组的血清CEA、CA125、CA153、CA199含量分别为5.6(1.0～619.0)μg/L、124.5(5.3～994.8)U/ml、14.4(3.1～800.0)U/ml、21.8(2.0～1200.0)U/ml,肺良性病变组分别为1.9(0.6～14.4)μg/L、17.7(1.8～303.6)U/m1、6.8(2.4～20.1)U/ml、9.3(2.0～82.6)U/ml,健康对照组分别为1.4(0.6～5.0)μg/L、9.6(4.4～36.5)U/ml、6.6(3.8～19.9)U/ml、6.4(2.0～58.1)U/ml.肺癌组血清CEA、CA125、CA153、CA199含量明显高于肺良性病变组和健康对照组(P均＜0.01);四项指标联合检测的敏感性为94.8%(55/58),明显高于单一检测[CEA:48.3%(28/58)、CA125:75.9%(44/58)、CA153:20.7%(12/58)、CA199∶31.0%(18/58)].结论 联合检测CEA、CA125、CA153、CA199可提高肺癌的阳性检出率.

Abstract：

Objective To evaluate the clinical value of combined detection of serum CEA, CA125,CA153 and CA199 in lung cancer diagnostec. Methods The serum level of CEA,CA125,CA153 and CA199 in 58 patients with lung cancer,38 patients with benign lung diseases and 40 healthy persons were determinated by Chemiluminesent immunoassay. The data were analyzed to evaluate the diagnostic value of the combination use of four markers. Results The serum levels of CEA,CA125,CA153 and CA199 in lung cancer group were 5.6 (1.0-619. 0) μg/L,124. 5 (5.3 - 994. 8) U/ml,14.4(3. 1 - 800. 0) U/ml and 21.8(2.0 - 1200.0) U/ml respectively ;The serum levels of CEA, CA125, CA153 and CA199 in benign lung diseases were 1.9 (0. 6 -14.4) μg/L, 17. 7 ( 1.8 - 303.6 ) U/ml, 6. 8 ( 2. 4 - 20. 1 ) U/ml and 9. 3 ( 2. 0 - 82. 6 ) U/ml respectively. The serum levels of CEA, CA125, CA153 and CA 199 in healthy controls were 1.4 (0. 6 - 5.0 ) μg/L, 9.6 (4. 4 -36. 5 ) U/ml,6. 6 (3.8 - 19. 9) U/ml and 6. 4 (2.0 - 58. 1 ) U/ml respectively. The levels of markers in the lung cancer group were significantly higher than those in patients with benign lung disease and healthy controllers (Ps ＜ 0. 01 ). The sensitivity of combined measurement was 94. 8%, significantly higher than a single measurement ( CEA 48. 3% ,CA125 75.9% ,CA153 20.7% ,CA199 31.0% ,Ps ＜0. 01 ). Conclusion The combined detection of CEA, CA125, CA153 and CA199 can significantly improve detection sensitivity of lung cancer and might provide valuable laboratory proof for early diagnosis of lung cancer.     

血清硫化氢浓度与APACHE Ⅲ评分在危重病患者预后中的应用价值

Objective To explore the prognosis value of serum hydrogen sulfide (H2S) concentration and acute physiology and chronic health evaluation HI (APACHE Ⅲ) scores in critically ill patients. Methods The serum H2S levels were measured in 72 cases and 12 controls by spectrophotometry. The APACHE Ⅲ scores of the patients were assessed. The relationship between serum H2S concentration and APACHE H scores and prognosis were analyzed. Results The average serum H2S concentration of the 72 cases was (45. 6 ±17.2) μmol/L The concentration in the survival group was(41. 1 ± 14. 7) μmol/L,and which was significantly lower than in the dead group(62. 8 ±15. 5)μmol/L,(P<0. 01). The average APACHE I score was(43. 6 ±26. 0)of the 72 cases. The APACHE Ⅲ score was(37. 7 ±22. 2) in the survival group,and which was significantly lower than in the dead group (65. 0 ±29. 6) (P <0. 01). The higher of the serum H2S concentration or APACHE Ⅲ scores,the higher mortality of the patients(P <0. 01). Conclusions Serum H2S levels and APACHE Ⅲ scores of critically ill patients have a role in judging the condition and prognosis of the patients.     

血清硫化氢浓度与APACHE Ⅲ评分在危重病患者预后中的应用价值

Objective To explore the prognosis value of serum hydrogen sulfide (H2S) concentration and acute physiology and chronic health evaluation HI (APACHE Ⅲ) scores in critically ill patients. Methods The serum H2S levels were measured in 72 cases and 12 controls by spectrophotometry. The APACHE Ⅲ scores of the patients were assessed. The relationship between serum H2S concentration and APACHE H scores and prognosis were analyzed. Results The average serum H2S concentration of the 72 cases was (45. 6 ±17.2) μmol/L The concentration in the survival group was(41. 1 ± 14. 7) μmol/L,and which was significantly lower than in the dead group(62. 8 ±15. 5)μmol/L,(P<0. 01). The average APACHE I score was(43. 6 ±26. 0)of the 72 cases. The APACHE Ⅲ score was(37. 7 ±22. 2) in the survival group,and which was significantly lower than in the dead group (65. 0 ±29. 6) (P <0. 01). The higher of the serum H2S concentration or APACHE Ⅲ scores,the higher mortality of the patients(P <0. 01). Conclusions Serum H2S levels and APACHE Ⅲ scores of critically ill patients have a role in judging the condition and prognosis of the patients.     

高糖危象患者血清瘦素和氧化应激的关系

Objective To investigate the relationship between the levels of serum leptin and oxidative stress in patients with hyperglycemia crisis. Methods A total of 96 patients with diabetic ketoaeidosis (DKA) and nonketotic hyperglycemia (NKH) were treated on a low-dose insulin protocol using intravenous infusion of insulin with the established rate of 0.1U·kg-1·h-1,with the patients on intravenous fluids and receiving nutrition by mouth and vein. The levels of serum leptin, 8-iso-prostaglandin F2α (8-iso-PGF2α, the activities of superoxide dismutase (SOD), total antioxidant capacity (TAC) and the contents of malondialdehyde (MDA) in 96 patients with hyperglycemia crisis on admission and after insulin therapy with resolution of hyperglycemia and ketoacidosis (72 hours) were measured. Another 35 healthy individuals served as normal control. Results The activities of SOD, TAC and the levels of leptin before treatment were lower in patients with hyperglycemia crisis than in normal controls, and the levels of MDA and 8-iso-PGF2a were more markedly elevated than those in normal controls (all P<0. 05). The activities of SOD, TAC and the levels of leptin in patients after treatment were significantly higher than those in patients before treatment, and the levels of MDA and 8-iso-PGF2a. were significantly lower than those in patients on admission (all P<0. 05). There was significant positive correlation between leptin and MDA in patients before treatment (r=0. 38, P<0. 05), and the level of leptin was negatively correlated with MDA and 8-iso-PGF2a in patients after treatment (r1 = - 0. 35, r2= - 0. 37, both P < 0. 05). In stepwise regression analysis, MDA and 8-iso-PGF2α showed a significant association with leptin. Conclusion The levels of leptin are significantly lowered in patients with hyperglycemia crisis. Oxidative stress may participate in determining the leptin level in hyperglycemia crisis.     

肿瘤标志物HE4、CA125、CA199、CA153、AFP在卵巢癌早期诊断中的应用价值

目的探讨肿瘤标志物血清人附睾蛋白4(HE4)、糖类抗原125(CA125)、糖类抗原199(CA199)、糖类抗原153(CA153)、甲胎蛋白(AFP)在早期卵巢癌诊断中的价值。方法选取2014年2月至2016年10月在该院治疗的卵巢肿瘤患者117例,其中卵巢癌组69例,卵巢良性病变组48例,同时选取健康自愿者70例为对照组,检测各受试者血清HE4、CA125、CA199、CA153、AFP水平。结果卵巢癌组HE4、CA125、CA199、CA153、AFP阳性率为59.42%、68.12%、33.33%、46.38%、39.13%,明显高于卵巢良性病变组和对照组(P0.05)。CA125诊断卵巢癌的灵敏度为68.11%,特异度为88.98%,阴性预测值为78.33%,阳性预测值为82.68%,约登指数为0.571,诊断效能优于其他肿瘤标志物指标。经病理检查,69例卵巢癌患者中,浆液性腺癌34例,黏液性腺癌18例,子宫内膜样癌17例。浆液性腺癌CA125阳性率为85.29%,明显高于黏液性腺癌和子宫内膜样癌(χ2=9.398,P0.05)。结论 CA125在卵巢癌早期诊断中有较好的应用价值,在浆液性腺癌中其阳性率较高。     

HE4和CA125联合检测对卵巢肿瘤鉴别诊断和病理分型的关系研究

目的探讨糖蛋白抗原125(CA125)与人附睾蛋白4(HE4)联合检测的临床价值。方法选取2013年6月至2015年8月收治的卵巢恶性肿瘤患者46例(恶性肿瘤组),卵巢良性肿瘤患者48例(良性肿瘤组),均检测血清CA125、HE4水平,并以ROC曲线评价其诊断价值,对不同病理分型患者CA125、HE4指标水平进行对比。结果 CA125最佳诊断切值为47.9U/L,血清CA125≥47.9U/L预测卵巢恶性肿瘤阳性的特异性为87.34%,敏感性为76.69%;HE4最佳诊断切值为55.68pmol/L,血清HE4≥55.68pmol/L预测卵巢恶性肿瘤阳性的特异性为90.34%,敏感性为83.01%;良、恶性卵巢肿瘤患者CA125与HE4水平差异具有统计学意义(P0.05);CA125、HE4联合检测诊断卵巢恶性肿瘤特异性与单独检测差异无统计学意义(P0.05),但敏感性明显高于单独检测,差异具有统计学意义(P0.05);卵巢上皮性肿瘤患者CA125、HE4水平较非卵巢上皮性肿瘤患者高,且差异具有统计学意义(P0.05);黏液性卵巢恶性肿瘤患者CA125、HE4水平显著低于浆液性卵巢恶性肿瘤患者,且差异具有统计学意义(P0.05)。结论通过联合检测血清CA125与HE4,可显著提高卵巢肿瘤鉴别诊断价值,且CA125与HE4在卵巢恶性肿瘤病理分型中具有辅助作用。     

HE4、CA125及CA72-4在子宫内膜异位症及卵巢癌中的诊断差异研究

目的 寻找互补的生物标记物来帮助鉴别诊断子宫内膜异位症或其他卵巢良性肿瘤与卵巢癌.方法 收集50例健康女性、17例良性卵巢肿瘤、57例子宫内膜异位症及39例卵巢癌患者的血液样本,并分析血清中的CA125、HE4及CA72-4的含量.结果 血清CA125含量在子宫内膜异位症及卵巢癌患者血清中升高,但在其他卵巢良性肿瘤未见明显变化.HE4仅在卵巢癌患者血清中显著升高（P＜0.05）,在子宫内膜异位症及卵巢良性肿瘤患者中未增加.此外,CA72 4在66.7％的卵巢癌患者血清中上升,与子宫内膜异位症相比,也有显著统计学意义（P＜0.05）.结论 在血清CA125水平较高的女性中,通过检测HE4及CA72-4水平可帮助鉴别诊断子宫内膜异位症与卵巢癌.     

血清CEA,CA125和HE4联合检测对卵巢癌的诊断价值

目的 探讨血清中癌胚抗原(carcinogenic antigen,CEA)、糖链抗原125(CA125)和人附睾蛋白4(human epididymis secretary protein 4,HE4)联合检测在卵巢癌诊断中的临床价值。方法 采用西门子CentaurXP全自动化学发光免疫分析仪检测37例卵巢癌患者(卵巢癌组),42例卵巢良性病变患者(良性病变组)及40例健康者(对照组)血清CEA,CA125和HE4水平,分析比较各组间三项指标水平的差异,三组三项指标单项及联合检测阳性率的比较; 通过敏感度、特异度、阳性预测值评价血清CEA,CA125,HE4联合检测对卵巢癌的临床诊断价值。结果 卵巢癌组与良性卵巢病变组血清CEA,CA125,HE4水平比较差异均有统计学意义(t=6.1,6.0,4.8,均P<0.05); 良性病变组CA125水平与对照组比较差异有统计学意义(t=4.7,P<0.05); CEA和HE4良性病变组与对照组比较差异无统计学意义(t=1.8,0.3,均P>0.05); 卵巢癌组血清CEA,CA125和HE4单项、两两联合和三项联合检测阳性率分别是:32.4%,70.3%,78.4%,75.7%,81.8%83.8%和89.2%。卵巢癌组与良性病变组CEA,CA125,HE4单项,两两联合和三项联合检测比较差异有统计学意义(χ²=13.4～49.4,均P<0.05),卵巢癌组与正常对照组CEA,CA125,HE4单项,两两联合和三项联合检测比较差异有统计学意义(χ²=20.0～49.5,均P<0.05); 三项联合检测敏感度为89.2%,高于各单项和两两联合检测的敏感度。结论 CEA,CA125和HE4三项联合检测敏感度高于各单项及两两联合检测的敏感度,三项联合检测能够提高卵巢癌的诊断水平。     

人血清附睾蛋白4和糖类抗原125联合检测对卵巢癌的诊断价值

目的：测定卵巢癌患者血清附睾蛋白4（HE4）和糖类抗原（CA）125水平,探讨血清HE4和CA125联合测定对卵巢癌的诊断价值。方法选择佛山市第一人民医院、佛山市第二人民医院、佛山中医院、佛山禅城区中心医院2012年1月至2013年5月收治的160例住院或门诊患者,将其分为卵巢癌组91例和卵巢良性肿瘤组69例。同时选择同期健康体检女性60例健康对照组。采用电化学发光免疫分析测定血清 HE4和CA125水平。并检测卵巢癌病理分期与 HE4、CA125水平的关系。结果卵巢癌患者血清 HE4、CA125水平均明显高于卵巢良性肿瘤组和健康对照组（P＜0．01）;指标单独检测,HE4敏感性、特异性和诊断效率均高于CA125;并联试验时,敏感性明显提高,串联试验时,特异性明显提高。单独和联合检测中,并联试验对卵巢癌阳性检出率最高。卵巢癌患者随着病理分期升高血清 HE4和CA125水平依次升高,但卵巢癌患者Ⅰ期血清CA125水平与卵巢良性肿瘤组比较,差异无统计学意义（P＞0．05）。结论与CA125相比,HE4为最佳单项卵巢癌肿瘤标志物,联合检测并联试验可提高诊断敏感性,串联试验可提高诊断特异性。     

检测CA125、CA153和CA72—4对卵巢癌诊断及疗效观察的临床价值

目的观察癌抗原125（CA125）、癌抗原153（CA153）、癌抗原72—4（CA72—4）对卵巢癌的诊断及疗效观察的价值。方法采用电发光法检测32例卵巢癌和21例妇科良性疾病患者血清中CA125、CA153和CA72—4水平。结果卵巢癌患者血清中CA125、CA153和CA72—4含量高于良性对照组,联合检测CA125和CA72—4特异性、敏感性优于单独检测及其它组合。卵巢癌患者治疗后CA125、CA153和CA72—4降低（P〈0．05～0．01）。结论联合检测CA125和CA72—4对卵巢癌的诊断有重要的临床价值,弥补了单独检测CA125的不足。     

HE4和CA125检测与病理学分类在罗同巢癌诊断中的相关性研究

目的探讨人血清附睾蛋白4（HE4）和糖蛋白抗原125（CAl25）在卵巢恶性肿瘤诊断中与病理学分类的符合率,同时探讨以上两种标记物对卵巢癌的灵敏度和特异性。方法将研究对象通过病理切片分为卵巢癌确认~H（50例1,卵巢良性病变组f50例1。健康妇女（50例1．同时用化学免疫发光的方法检测上述对象的HE4及CAl25血清浓度。结果在卵巢恶性病变过程中,通过病理确诊是否患卵巢癌,CAl25对卵巢癌病人的灵敏度和特异性分别为57％和68％,HE4对患卵巢癌各期的灵敏度和特异性为94％和96％。结论HE4在卵巢癌患者中高表达。与病理结果符合率较高：CAl25在卵巢癌灵敏度特异性低．与病理诊断符合率低．且CAl25对早期卵巢癌患者存在着一定的误诊漏诊,HE4是比CAl25更能反映患卵巢癌的一个指标。     

CA125与CA72-4联合检测在卵巢癌诊断中的应用

目的探讨癌抗原125(CA125)、癌抗原72-4(CA72-4)联合检测对卵巢肿瘤诊断的价值。方法采用电化学发光法测定54例卵巢癌患者、41例卵巢良性肿瘤患者和40例健康妇女血清中的CA125和CA72-4水平。结果卵巢癌患者血清CA125和CA72-4水平明显高于健康对照组(P<0.05);CA125和CA72-4单项检测诊断卵巢癌的阳性率分别为65.8%和20.3%,均低于联合检测的阳性率(81.5%);联合检测的敏感度(81.5%)和准确性(87.4%)均明显高于单项检测(P<0.05)。结论联合检测CA125和CA72-4对卵巢恶性肿瘤的诊断和鉴别具有重要意义。     

血清CA125在卵巢癌诊断及预测分期中的应用价值

目的探讨血清CA125在卵巢癌诊断及预测分期中的应用价值。方法我院妇产科2001年1月—2010年10月收治卵巢癌病人520例,测定其血清CA125水平,并分析其与卵巢癌病理组织学类型、临床分期的关系。结果 520例卵巢癌病人中上皮性卵巢癌组血清CA125水平与生殖细胞肿瘤组及性索间质肿瘤组比较明显增高（F=9.466,P〈0.01）;上皮性卵巢癌组中浆液性囊腺癌CA125水平与黏液性腺癌及透明细胞癌相比明显增高（F=7.399,P〈0.01）;Ⅲ～Ⅳ期组CA125的水平明显高于Ⅰ～Ⅱ期组（F=54.720,t=7.852,P〈0.01）;低分化组血清CA125水平明显高于高、中分化组（F=47.031,t=6.880,P〈0.01）;血清CA125含量〉46.36kU/L时,上皮性卵巢癌的诊断价值最高,对应的诊断灵敏度为82.6%,特异度为61.8%;当CA125〉150kU/L时,晚期病人诊断灵敏度、特异度及准确率分别为85.66%、59.22%及75.48%,此时对卵巢癌晚期诊断意义大。结论血清CA125对上皮性卵巢癌的诊断具有较高价值,尤其是上皮性浆液性囊腺癌病人血清CA125水平升高明显;晚期（Ⅲ～Ⅳ期）以及低分化病人CA125水平较高;CA125诊断价值的最佳临界点高于普遍认为的阳性诊断标准,当CA125〉150kU/L时,对晚期病人诊断意义较大。     

CA125和HE4联合检测在早期卵巢癌诊断中的应用价值

目的：研究血清糖类抗原125（CA125）和人附睾蛋白4（HE4）联合检测对早期卵巢癌诊断的应用价值。方法选取本院2014年1月至2015年12月88例卵巢癌患者作为观察组（卵巢组）,70例良性卵巢囊肿患者作为良性肿瘤对照组,同期健康体检70例作为健康对照组,采用电化学发光法检测血清CA125、HE4,比较三组患者的血清 HE4和CA125水平差异。结果卵巢癌组血清 HE4、CA125显著高于良性肿瘤组及健康对照组,有统计学差异（P＜0．05）。HE4、CA125联合检测灵敏度显著高于单独检测 HE4、CA125,具有统计学差异,（P＜0．05）。联合检测特异性与单独检测无统计学差异（P＞0．05）。结论血清CA125和HE4联合检测可显著提高早期卵巢癌诊断的敏感性及准确性。